Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 30

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 30
---
 last (15 out of 15) STAAR management financial projections show a (17%) decline in Net Sales from 2024-2025E; no company in Broadwood’s peer set had declining revenue O P Broadwood’s valuation analysis is flawed because the financial performance of its selected peer set is not comparable to STAAR given STAAR’s lower growth profile Source: FactSet. Market data as of 8/1/2025. (1) Projections using management estimates from the definitive proxy. Broadwood's Claimed Value is Not Supported by STAAR’s Projected Financial Performance Broadwood Peer Median has ~3x the growth rate compared to STAAR’s growth projections, resulting in an overstated valuation analysis by Broadwood 2024-2027E Net Sales CAGR Broadwood Peer Median 19% 6%(1) EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS C

Broadwood’s claim that Alcon previously offered to pay much more for STAAR ignores the fact that Alcon withdrew its offer after diligence of underlying sales and demand concerns “Less than a year ago, Alcon was in fact prepared to pay much more for STAAR. In October 2024, Alcon submitted a proposal to acquire the Company for $55 per share in cash plus a contingent value right that was worth approximately $7 per share” Broadwood Claims The Reality… Alcon withdrew its $55 + $7 CVR per share proposal after substantial due diligence that showed STAAR’s structural challenges $55 + $7 CVR per share was no longer available for the Board to consider Prior price is not supported due to structural challenges facing STAAR, as reflected in STAAR's financial results and growth profile. STAAR’s stock price declined to $16.48 per share upon announcement of 4Q 2024 results O P Comparison of 2 Year Net Sales CAGR Preceding Alcon’s October 2024 & July 2025 Offers Source: Company filings, FactSet, and Wall Street research. Note: Market data as of August 4, 2025. (1) Represents sales over the last twelve months (LTM). Growth Profile Declined Since Alcon’s October 2024 Offer (27%) LTM(1) 2Q22 – LTM(1) 2Q24 Net Sales CAGR October 2024 Offer LTM(1) 2Q